Skip to content

Oncopeptides Present Phase 2 Clinical Data at the European Hematology Association in Copenhagen, Denmark, June 2016

Stockholm, Sweden

Oncopeptides AB, a clinical stage company developing the peptidase targeted therapy – melflufen – announced that clinical results from a Phase 2 study of melflufen and dexamethasone in patients with relapsed-refractory multiple myeloma was presented on poster P281 at the 21th European Hematology Association Congress in Copenhagen, Denmark, June 7 – 11.

The poster is entitled ‘Final Phase 2 Study Data of Melflufen and Dexamethasone for patients with Relapsed-Refractory Multiple Myeloma’ and can be downloaded here.

CEO, Jakob Lindberg commented “The results to date support our belief that melflufen has the potential to make a meaningful difference in the lives of patients with relapsed-refractory multiple myeloma, providing a reliable go-to alternative even when conventional therapies have failed”.

Multiple myeloma is the second most common hematological cancer and in 2016, it is estimated that in the US there will be 30,330 new cases of myeloma and an estimated 12,650 people will die of this disease1. In 95% of cases the patient’s cancer has metastasized, which today, has a five-year survival rate of 47.4%1.

For further information, contact:

Jakob Lindberg CEO
Oncopeptides AB, Stockholm, Sweden
Tel: +46 (0) 705 695 471